← Back to Screener
Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX)
Price$3.79
Value ScoreC
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-22.68%
Price vs S&P 500 (4W)0.93%
VGM Score48.79
Market Capitalization$1.91B
All Metrics
Book Value / Share (Quarterly)$1.93
P/TBV (Annual)2.59x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)23.30%
Cash Flow / Share (Quarterly)$-0.62
Price vs S&P 500 (YTD)-23.16%
Gross Margin (TTM)7.22%
Net Profit Margin (TTM)-842.93%
EPS (TTM)$-1.20
10-Day Avg Trading Volume20.38M
EPS Excl Extra (TTM)$-1.20
Revenue Growth (5Y)79.93%
EPS (Annual)$-1.44
ROI (Annual)-56.09%
Gross Margin (Annual)4.99%
Net Profit Margin (5Y Avg)-964.06%
Cash / Share (Quarterly)$1.24
Revenue Growth QoQ (YoY)-56.11%
ROA (Last FY)-43.74%
Revenue Growth TTM (YoY)11.07%
EBITD / Share (TTM)$-1.06
ROE (5Y Avg)-51.25%
Operating Margin (TTM)-881.32%
Cash Flow / Share (Annual)$-0.72
P/B Ratio1.86x
P/B Ratio (Quarterly)1.58x
Net Income / Employee (Annual)$-1,074,600
EV / Revenue (TTM)19.09x
Net Interest Coverage (TTM)-63.75x
ROA (TTM)-40.60%
EPS Incl Extra (Annual)$-1.44
Current Ratio (Annual)5.50x
Quick Ratio (Quarterly)5.38x
3-Month Avg Trading Volume16.44M
52-Week Price Return-19.33%
Revenue / Employee (TTM)$110,700
Tangible BV / Share (Quarterly)$1.38
P/S Ratio (Annual)25.51x
Asset Turnover (Annual)0.05x
52-Week High$7.18
Operating Margin (5Y Avg)-980.12%
EPS Excl Extra (Annual)$-1.44
CapEx CAGR (5Y)2.10%
26-Week Price Return-6.75%
Quick Ratio (Annual)5.42x
13-Week Price Return-4.77%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)5.47x
Enterprise Value$1.27B
Revenue / Share Growth (5Y)46.90%
Asset Turnover (TTM)0.05x
Revenue / Employee (Annual)$124,500
Pretax Margin (Annual)-863.53%
Cash / Share (Annual)$1.41
3-Month Return Std Dev56.15%
Net Income / Employee (TTM)$-933,000
ROE (Last FY)-57.01%
Net Interest Coverage (Annual)-41.35x
EPS Basic Excl Extra (Annual)$-1.44
Receivables Turnover (TTM)258.80x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-1.20
Receivables Turnover (Annual)2343.71x
ROI (TTM)-53.30%
P/S Ratio (TTM)28.69x
Pretax Margin (5Y Avg)-966.30%
Revenue / Share (Annual)$0.17
Tangible BV / Share (Annual)$1.56
Price vs S&P 500 (52W)-47.53%
Year-to-Date Return-12.22%
5-Day Price Return19.27%
EPS Normalized (Annual)$-1.44
ROA (5Y Avg)-38.13%
Net Profit Margin (Annual)-863.35%
Month-to-Date Return3.76%
Cash Flow / Share (TTM)$-1.38
EBITD / Share (Annual)$-1.36
Operating Margin (Annual)-880.86%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-50.78%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-1.20
P/TBV (Quarterly)2.22x
P/B Ratio (Annual)1.88x
Pretax Margin (TTM)-849.83%
Book Value / Share (Annual)$2.14
Price vs S&P 500 (13W)-14.52%
Beta1.03x
Revenue / Share (TTM)$0.13
ROE (TTM)-54.32%
52-Week Low$2.77
vGradeC
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.22est. -0.28
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.71
3.71
3.71
3.71
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock | C | C | C | $3.79 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Recursion Pharmaceuticals is a clinical-stage biotech company that integrates computational and experimental technologies—including chemistry, automation, and data science—to accelerate drug discovery and industrialize development. The platform aims to decode biological processes and de-risk the path from research to therapeutic approval. U.S. operations represent the company's primary revenue source, with additional presence in the United Kingdom and other markets.